A novel biomarker test to predict therapy selection for Inflammatory Bowel Disease

“免疫介导的疾病，包括自身免疫性和炎症性疾病，是常见的，使人衰弱的和非常异质的：两个被诊断患有同一疾病的患者可能会遵循明显不同的临床过程。对于许多自身免疫性疾病，现在可以获得有效且通常昂贵的治疗方法。然而，它们诱导的免疫抑制也导致大量的副作用。因此，越来越需要临床检测，使医生能够在正确的时间为正确的患者定制这些潜在毒性的免疫抑制疗法。然而，目前还没有强大的临床或生物标志物检测方法，可以在这些疾病中进行个性化治疗靶向。PredictImmune正在开发开创性工具，用于指导免疫介导的炎症性疾病的治疗选择，其第一个产品针对炎症性肠病（克罗恩病和溃疡性结肠炎）。为了充分实现炎症性肠病个性化医疗的目标，有必要证明不仅仅是预测，而且还表明如果积极治疗与预测遵循积极疾病过程的患者相匹配，则可以改善临床结果。这将是可行性研究的目标。"

"Immune-mediated diseases, including autoimmune and inflammatory diseases, are common, debilitating and immensely heterogeneous: two patients diagnosed with the same disease may follow markedly different clinical courses. For many autoimmune diseases, effective and often expensive treatments are now available. However, the immunosuppression they induce also results in substantial side effects. Consequently, there is an increasing need for clinical assays that allow physicians to tailor these potentially toxic immunosuppressive therapies to the right patients at the right time. However, there are currently no robust clinical or biomarker assays that allow personalized therapeutic targeting in these diseases.PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with its first product addressing inflammatory bowel disease (both Crohn's disease and ulcerative colitis).In order to fully achieve the goal of personalized medicine in inflammatory bowel disease, it is necessary to demonstrate more than just prediction but also to show that clinical outcomes can be improved if aggressive therapy is matched to patients predicted to follow an aggressive disease course. This will be the goal of the feasibility study presented here."